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1. Introduction
The incidence of ovarian cancer in 2008 was projected to be 225,500 new cases and 140,200
deaths worldwide, representing 3.7% of all female cancers and 4.2% of all cancer deaths in
women [1]. Ovarian cancer, one of the major causes of death from cancer in women, is
commonly diagnosed at an advanced stage. Cytoreductive surgery followed by chemotherapy
combining platinum and taxane is currently the standard treatment for ovarian cancer [2].
Ovarian cancer is one of the most sensitive solid tumors, with objective responses ranging from
60 to 80% even in patients with advanced stage. However, most patients ultimately recur and
develop resistance to platinum and taxane.
Resistance to chemotherapy presents a major obstacle in attempting to improve the prognosis
of patients with ovarian cancer. Accordingly, it is important to elucidate the mechanisms of
chemoresistance to manage ovarian cancer. Recently, the biological characteristics of ovarian
cancer have been clarified. It has long been known that ovarian cancers of serous histology
appear to be more sensitive to chemotherapy than other histological subtypes. Patients with
clear cell carcinoma or mucinous adenocarcinoma of the ovary showed a significantly worse
prognosis in a retrospective review of several Gynecologic Oncology Group (GOG) trials [3].
Therefore, it is important to determine optimal regimens based on histological subtype. In this
chapter, clear cell carcinoma and mucinous adenocarcinoma of the ovary are discussed.
2. Clear cell carcinoma
Clear cell carcinoma (CCC) has unique clinical and biological features [4]. In North America and
Europe, CCC is the third most common histological subtype of epithelial ovarian cancer (EOC),
with an estimated prevalence of 1-12% [5, 6]. For unknown reason, CCC comprises more than
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20% of such cancers in Japan [7-9]. Interestingly, among Asian women living in the United States,
CCC was diagnosed twice as frequently (11.1%) compared to Caucasians (4.8%) [10].
Several studies have analyzed the risk factors for ovarian cancer by histologic subtype. CCC
was associated (odds ratio: 2.2-2.3) with an increased body mass index (BMI 30) [11, 12].
However, in the NIH-AARP Diet and Health Study BMI was correlated only with endome‐
trioid histology [13].
It has long been recognized that CCC often is associated with endometriosis (22-70%), where‐
as hobnail cells bear a very strong morphological resemblance to endometrial Aria-Stella cells
[14, 15]. Several studies have reported that endometriosis frequently shows a sequential change
to EOC, including CCC. Therefore, atypical endometriosis is considered to be a precancerous
change. Ovarian cancers associated with endometriosis tend to occur in younger women, and
present 5-6 years earlier, on average, than high-grade serous carcinoma (HGSC) [16]. In National
Cancer Institute Surveillance, Epidemiology and End Results (SEER) data, women with CCC
were younger than patients with serous adenocarcinoma (SAC) (55 vs. 64 years; median age) [10].
An increased incidence of vascular thromboembolic complications is seen in patients with CCC
[17, 18]. Up to 40% of patients with CCC may develop thromboembolic disease and this rate
is double that in matched non-CCC controls with ovarian cancers [19].
3. Clinicopathological features
Ovarian CCC usually presents as a large pelvic mass [20, 21]. The size of masses range from 3
to 20 cm, with most tumors detected preoperatively either by clinical examination or imaging.
Recent reports involving large institutional cohorts compared early-stage (I/II) to advanced-
stage ovarian cancers (III/IV) and showed that 57-81% of CCC were diagnosed at an early stage
[9, 22]. In SEER data, 56% of CCC were stage I, compared to 19% for SAC [10]. Combining the
low overall incidence of CCC and their early stage propensity, CCC may make up only 1-5%
of advanced stage patients in chemotherapy trials, largely due to their overall low incidence
and tendency for early stage distribution at the time for initial diagnosis [6].
Sugiyama, et al. [9] retrospectively reviewed 101 patients with CCC in Japan who underwent
complete surgical staging to determine clinicopathological features of CCC. Histologic
evaluation was performed under central pathological review. Tumors were diagnosed as CCC
if the following appeared in 90% or more of all specimens: a small to large sheet of polyhedral
clear cells with delicate fibrovascular septa, tubules and papillae, clear or hobnail, or eosino‐
philic cells of organoid appearance, or clear cells with coalescent vacuoles containing "targe‐
toid" eosinophilic PAS-positive globules. Of the 662 patients with EOC, 101 (15.3%) had CCC
and 235 (35.5%) SAC. All patients underwent complete surgical staging, including intraperi‐
toneal cytology, bilateral salpingo-oophorectomy, hysterectomy, omentectomy, pelvic-/
paraaortic lymphadenectomy, and aggressive cytoreductive surgery for advanced cases.
Ninety-seven (96%) of 101 patients with CCC and 229 (97%) of 235 with SAC underwent
platinum-based chemotherapy after initial surgery.
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The median age did not differ between patients with CCC and those with SAC. The percentage
of patients at stage I was significantly higher in CCC than SAC (16.6%), while significantly
fewer patients were at stage III had CCC than SAC (61.7%). By contrast, the incidence of stage
III was significantly lower in CCC than in SAC. Recurrence in patients with CCC occurred in
29% of stage I patients, 30% of stage II, 62% of stage III, and 73% at stage IV. Although none
of the patients with stage Ia CCC relapsed, 14 of 38 patients (37%) with stage Ic did relapse.
In stage III disease the median survival time was significantly shorter for patients with CCC
than those with SAC. The survival rate for patients at stage III was significantly lower in the
CCC group than in the SAC group. Although estimated survival rates at 3 and 5 years in
patients with no gross tumor did not differ significantly between CCC and SAC, survival rates
in both patients with <2 cm and >2 cm residual disease were significantly lower in CCC than
in SAC. Jenison, et al. [23] showed that the survival rates for CCC were consistently lower in
each of the FIGO stages compared with SAC, although there was no statistical significance. In
their study, median survival time for stage I patients with CCC was significantly shorter than
that for those with SAC. Similarly, the survival rate for patients with stage Ic CCC was lower
compared with patients with stage Ic SAC. Additionally, the median survival time for stage I
patients with CCC was worse than those with SAC (31.8 months vs 42.3 months) and the time
to recurrence in patients with stage I/II CCC was definitely shorter (12.2 months) [9]. Twenty-
seven patients with stage III/IV CCC had measurable disease after initial surgery. The overall
clinical response rate for SAC was 72.5%. In contrast, only three (11.1%) of 27 patients re‐
sponded to platinum-based chemotherapy in CCC. Patients with CCC showed a very low rate
of response and a high incidence of progressive disease. Another authors demonstrated that
platinum-based chemotherapy did not appear to improve the survival of patients with CCC,
compared with survival after non-platinum-based chemotherapy [24]. Additionally, CCC
patients with residual tumor showed a high recurrence rate (Fig 1). CCC has a more aggressive
course and a more malignant behavior than SAC. Therefore, new treatment strategies for CCC,
including alternative regimens of chemotherapy, should be established.
4. Mechanisms of platinum resistance in CCC of the ovary
There is general acceptance of CCC that is insensitive to conventional platinum-based
chemotherapy lead to a poor prognosis. Resistance to cisplatin (CDDP) is an important factor
in the poor prognosis of patients with CCC. Several mechanisms involved in drug resistance
have been proposed as explanations, including decreased drug accumulation, increased drug
detoxification, increased DNA repair activity, and activation of receptor tyrosine kinases and
its downstream signaling pathways [25-29].
Adenosine 5’-triphosphate (ATP)-binding cassette (ABC) transporters, such as ABCB1 (also
known as P glycoprotein), ABCC1 (multidrug resistance associated protein-1) and ABCC3, are
known to lower intracellular drug concentrations and are important multidrug resistance
factors [30]. An immunohistochemical study of ABCB1 and ABCC1 in CCC and SAC tumors
revealed that their expression of these transporters did not differ between CCC and SAC [31].
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In addition, no significant differences were observed in the expression of ABCB1 and ABCC1
between responders and non-responders to platinum-based chemotherapy in both tumor
types. These results suggest that multidrug resistance proteins do not contribute to chemore‐
sistance in CCC. Ohishi, et al. [32] examined the expression of mRNA by ABCC superfamily
members, ABCC1, ABCC2, and ABCC3, in CCC and SAC tumors. They found that only ABCC3
genes were expressed significantly more in CCC than SAC. Therefore, they concluded that
increased expression of ABCC3 may, at least in part, be associated with the chemoresistant
phenotype of CCC.
Several drug detoxification systems also can diminish intracellular drug activity. Cellular
detoxification via the glutathione system is known to be involved in the metabolism of various
cytotoxic agents, including the platinum agents, etoposide (VP-16), and mitomycin C (MMC)
[27, 28, 33, 34]. Indeed, the glutathione concentrations in CCC cell lines increased significantly
after exposure to CDDP or MMC [35]. A gene expression study showed that glutathione
peroxidase 3 (GPx3), glutaredoxin (GLRX), and superoxide dismutase (SOD2) were expressed
highly in CCC tumors and that the elevated levels of these, and perhaps other, antioxidant
proteins may render the tumors more resistant to chemotherapy [36].
Nucleotide excision repair (NER) is a multienzyme DNA repair pathway in eukaryotes that
has been implicated in drug resistance in human tumor cells [37]. Reed, et al. [38] examined
the mRNA expression of two key genes, excision repaircross-complementing rodent repair
deficiency, complementation group 1 (ERCC1) and xeroderma pigmentosum group B (XPB),
that are involved in the NER pathway of EOC tumors. Expression of ERCC1 and XPB were
higher in CCC tumors than in other histological tumor types. This phenomenon may be related
to de novo drug resistance against chemotherapeutic agents in CCC. DNA mismatch repair
systems (MMR), which correct errors that occur during DNA replication, also play a critical
role in the sensitivity of DNA damaging agents. In experimental systems, cells deficient in
0 
20 
40 
60 
80 
100 
C
u
m
u
la
tiv
e 
pe
rc
en
t (
%
) 
0 20 40 60 80 100 120 140 
Survival time (months) 
RT=0cm 
RT<1cm 
RT>1cm 
p=0.04 
Median progression-free survival duration (months) 
39 
 7 
 5 
Figure 1. Progression free survival rate for stage III and IV patients, and residual tumor diameter. Progression free sur‐
vival rates for the patients without residual disease were significantly greater, but there was no significant difference
between those with <1 cm residual disease and with >1 cm. RT: residual tumor diameter
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MMR are highly tolerant to the methylating chemotherapeutic drugs streptozocin and
temozolomide and, to a lesser extent, CDDP and doxorubicin [39]. Loss of MMR may be caused
either by a germline mutation of two major MMR genes, hMLH1 or hMSH2, or by somatic
MMR gene inactivation through epigenetic silencing via methylation of the hMLH1 promoter.
Cai, et al. [40] reported that elevated expression of hMLH1 and hMSH2 proteins are involved
in the development of a subset of CCC, and that there is a strong correlation between alterations
in the expression of hMLH1 and hMSH2 and the presence of MSI in CCC tumors.
Epidermal growth-factor receptor (EGFR) and v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2 (ERBB2; HER2) are cell-surface-receptor tyrosine kinases and can activate both the
signaling pathways of mitogen-activated protein kinase and phosphatidylinositol 3’-kinase
(PI3K)-Akt [41]. Activating these pathways leads to phosphorylated Bc1-2 antagonist cell death
(BAD) and B-cell leukemia/lymphoma (Bcl)-2, thereby inhibiting chemotherapy-induced
apoptosis [42]. An immunohistochemical study showed found EGFR in 61% of CCC tumors
[43]. Molecular analyzes of various types of ovarian tumors showed HER2 to be overexpressed
in CCC relative to other major histological types of EOC [44]. In ovarian cancer, the HER2
protein is overexpressed as a consequence of HER2 gene amplification in 20 to 25% of cases
and predicts a poor prognosis [45, 46].
Cell proliferation is controlled by cyclin-dependent kinases (CDK), which are regulated by
cyclin binding, phosphorylation, and CDK inhibitors (e.g. p16, p21, and p27) [47]. p53, known
as a tumor suppressor protein, also up-regulates expression of p21 and causes cell the cycle to
arrest at G1. Changes in the p53 gene are seen in 50 to 70% of cases of advanced serous
adenocarcinoma [48, 49]. In contrast, the p53 mutation is rare in CCC, and immunohistochem‐
ical staining shows that CCC tends to express little or no p53 protein [50]. Cytotoxic drugs are
primarily effective against proliferating cells; therefore, quiescent cells show a degree of
resistance relative to cycling cells [51]. Dimanche-Boitrel, et al. [52] reported that less intracel‐
lular drug accumulates in resting cells. Itamochi et al. examined the proliferation activity and
CDDP sensitivity of 11 CCC and 5 SAC cell lines, and this found that the doubling time for
CCC cells was significantly longer than for SAC (61.4 vs 29.8 h) [7]. There was a significant
reverse correlation between the S-phase fraction and the response to CDDP. These findings
may relate to the high incidence of stage I patients with CCC, and also suggests that the
resistance of CCC to CDDP may be caused by low cell proliferation. In addition, Ki-67, a
nuclear antigen expressed in all states of the cell cycle except in resting cells in G0, has a
significantly lower labeling index in CCC than in SAC [31]. Furthermore, a significantly higher
Ki-67 labeling index (LI) is observed in responders than in non-responders in both CCC and
SAC tumors.
The 5-year survival rate for high LI patients (over 18.4%; mean value for CCC) was significantly
greater than that for low LI (less than 18.4%) ( 46.3% vs. 9.2%, p<0.05) (Fig. 2). A multivariable
analysis revealed that the Ki-67 labeling index and residual tumor size were independent
prognostic factors. Other authors have reported that immunohistochemical staining of CCC
reveals a low expression of Ki-67, p53, and cyclin A, and significantly increased expression of
both p21 and cyclin E, which are other histological subtypes [53]. These results suggest that
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CCC has low tumor proliferation activity and that this low proliferation activity in CCC could
be associated with chemoresistance.
Figure 2. Estimated survival rates for patient with clear cell carcinoma. When the cut-off value of Ki-67 labeling index
(LI) was set at 18.4% (the mean value of clear cell carcinoma), the estimated 5-year survival rate for elevated Ki-67 LI
patients was significantly greater than that for low Ki-67 LI (46.3% vs. 9.2%).
5. Future directions
The clinicopathological features of CCC suggest that a new strategy for chemotherapy in CCC
should be adopted, focusing on new agents without cross-resistance to platinum agents.
Several anticancer agents with no cross-resistance to platinum analogues, such as paclitaxel
(PTX), VP-16, and camptothecin (CPT-11) have been developed.
Activating the PI3K/Akt pathway and its downstream signaling mammalian target of rapa‐
mycin (mTOR) seems to indicate drug resistance and poor prognosis in many cancers. It has
been reported that CCC has a high frequency of activating mutations of PIK3CA [54]. Because
it is known well that activation of Akt signaling results in hypersensitivity to mTOR inhibition,
CCC may be a good candidate for therapy with an mTOR inhibitor. Several clinical trials have
shown potential antitumor activities for mTOR inhibitors (everolimus, deforolimus, and
temsirolimus) in solid tumors. Temsirolimus (CCI779, a synthetic, ester analog of rapamycin)
is indicated to treat advanced renal cell carcinoma. A phase II study is ongoing to evaluate the
safety and efficacy of temsirolimus in combination with carboplatin and PTX followed by
temsirolimus consolidation as first-line therapy for patients with stage III-IV CCC in the ovary
(NCT01196429, ClinicalTrials.gov). We hope this combination therapy will improve the
survival of patients with ovarian CCC.
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6. Mucinous adenocarcinoma
Ovarian mucinous adenocarcinoma (MAC) is divided into intraepithelial and invasive
carcinomas (Fig. 3). Intraepithelial mucinous carcinoma is characterized by marled epithelial
atypia in the absence of stromal invasion. Invasive mucinous carcinoma is diagnosed once
stromal invasion measuring more than 5 mm or more than 10 mm2 is detected. Two types of
invasive mucinous caricinoma are recognized: expansile and infiltrative. The former is
characterized by conflicted glandular growth uninterrupted by normal ovarian parenchyma,
while the latter demonstrates a presence of small glands, nests or individual cells infiltrating
the stroma.
Figure 3. Criteria for central pathological review.
Intraepithelial mucinous carcinoma, FIGO stage I, has a recurrence rate of 5.8% [55]. Invasive
mucinous carcinoma, FIGO stage I, has a 5-year survival rate of 91%. Patients with advanced
tumors usually die of the disease [56]. Invasive mucinous carcinoma with an infiltrative pattern
has a more aggressive course than mucinous carcinoma with an expansile pattern. Interest‐
ingly, invasive mucinous caricinoma of the ovary often coexistes alongside areas of mucinous
borderline lesions and benign mucinous cystadenomas, suggesting that these lesions may be
precursors to invasive tumors [57].
Winter, et al. [3] reviewed the data from 6 GOG phase III trials of adjuvant chemotherapy with
CDDP and PTX in women with stage III EOC after primary debulking surgery, both optimal
and suboptimal. Of the 1,895 patients included in these 6 studies, 74% had SAC, while only
2% had MAC. The authors found that women with mucinous tumors had a progression-free
survival of 10.5 months, compared to 16.9 months for women with serous tumors. Women
with MAC had a relative risk of progression of 2.18 compared their serous counterparts
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(p<0.001) [69]. The relative risk of death from MAC for compared to SAC was 4.14 (p<0.001).
Shimada, et al. [58] compared 24 women with primary MAC to 189 women with SAC and
found response rates to platinum-based regimens of 12.5 % and 37.7% respectively. Pectasides,
et al. [59] compared 47 women with advanced stage primary MAC to 94 with advanced-stage
SAC, all of whom had received a platinum-based regimen in 1 of 9 Hellenic Cooperative
Oncology Group studies. The authors found a better response rate in women with SAC (70%
for serous vs 38.5 % for mucinous), although this did not translate into survival differences
between the 2 groups.
7. Clinicopathological features
Seidman, et al. [60] carefully reviewed the pathology of 220 consecutive cases of epithelial
ovarian cancer. After excluding carcinosarcomas and primary peritoneal cancers, they found
the incidence of primary MAC to be 3.4%. Other authors reviewed 1400 cases of EOC from 14
centers in Japan [58]. In this large group, 16% patients had an initial diagnosis of invasive
primary mucinous ovarian cancer. However, after a careful pathologic review, only 4.9% had
invasive primary ovarian cancer, with the remainder reclassified as either mucinous intraepi‐
thelial carcinoma, mucinous borderline tumors, or metastases from another site. Seidman and
colleagues argue that these lower estimates are likely a more accurate reflection of the incidence
of mucinous ovarian cancer because the following problems were likely in the literature: (1)
misclassification of a gastrointestinal primary tumor as an ovarian primary tumor (80% of
mucinous epithelial tumors found in the ovary are extraovarian in origin); (2) misclassification
of a mucinous borderline tumor as an invasive cancer; and (3) classification of pseudomyxoma
peritoneii as being of ovarian origin when it is now standard to consider all such cases as
intestinal in origin.
Mutations in KRAS, BRCA, and p53 are the most frequently studied single gene alterations in
ovarian cancer pathogenesis. Some investigators have gone beyond analysis of single gene
mutations and have used gene expression analysis to evaluate differences between serous and
mucinous ovarian carcinomas. Marchini, et al.[61] carried out genomic analyses using a
microarray chip with 16,000 genes and found that serous and mucinous tumors were easily
distinguished on the basis of expression profiles. Using a probe set of 59,000 genes, Heinzel‐
mann-Schwarz, et al. [62] likewise found clear separation in expression profiles between serous
and mucinous tumors of the ovary.
The role of the KRAS oncogene has been explored extensively in EOC. The RAS family of G
proteins is part of the pathway that signals cell division. Mutations in the RAS genes have been
found to stimulate cell growth [63]. In the literature, 50% of MAC had KRAS mutations,
compared to only 5% of SAC, 10% of endometrioid ovarian caricinomas, and no CCC [64].
Interestingly, the same KRAS mutations found in invasive mucinous tumors also are found in
adjacent borderline and benign mucinous lesions in the same specimens [65].
Mutations of BRCA1 and BRCA2 are thought to play a significant role in developing SAC but
not MAC. BRCA1 and BRCA2 are tumor suppressor genes that help to repair damaged DNA
Ovarian Cancer - A Clinical and Translational Update104
and are commonly mutated not only in inherited SAC but also in many cases of sporadic SAC.
Tonin, et al. [66] reviewed the histopathologic subtypes of ovarian carcinomas in 58 families
with hereditary breast and ovarian carcinomas. In those patients with known BRCA mutations,
64% had SAC, and only 2% had MAC. In contrast, among women with ovarian cancer negative
for BRCA mutation, 29% had MAC, and this proportion was significantly higher than among
women with BRCA mutation. Similarly, in a review of the literature that included 636 BRCA
mutation-positive women with ovarian cancer, only 2% were found to have mucinous
subtypes. p53 also seems to play a prominent role in carcinogenesis of serous ovarian tumors
but not mucinous ovarian tumors [70]. Mutations in p53 have been found in almost 60% of
serous tumors but in only 16% of mucinous tumors.
The expression of multiple individual proteins has been examined in serous and mucinous
tumor specimens using immunohistochemical stains. Compared to serous tumors, mucinous
tumors are more likely to express E-cadherin (62% vs. 4%, p<0.001) and less likely to stain
positive for N-cadherin (8% vs. 68%, p<0.001). The cadherin family of glycoproteins helps cells
establish contact with other cells and stabilize tissue architecture. The matrix metalloprotei‐
nases, which also play a role on cell migration and adhesion, have also been found to be
expressed differently between serous and mucinous tumors. Kobel, et al. evaluated 21 proteins
with immunohistochemistry in 500 ovarian cancer specimens. They found different expression
between serous and mucinous subtypes in 20 of the 21 biomarkers they examined, including
p53, cadherin, metalloproteinase, CA125, and WT-1. Collectively, these and other molecular
studies point toward a distinct pathogenesis of MAC compared to other histological subtypes
of ovarian cancer.
The majority of MAC are either well or moderately differentiated and this contributes to the
low risk of relapse for FIGO stage I tumors. It also is known that patients at an early stage show
good outcomes. On the other hand, patients with advanced mucinous adenocarcinoma are
recognized to have poorer outcomes. There was no significant difference in survival between
mucinous invasive adenocarcinoma and SAC in patients with optimal surgical management
[58]. In contrast, patients with suboptimal therapy showed a significantly worse prognosis
than those with SAC (Fig 4).
When a mucinous tumor is grossly limited to the ovary, there is little chance of occult lymph node
metastasis. Cho, et al. [71] reviewed 26 cases of MAC noted to be grossly stage I intraoperative‐
ly. All of these patients underwent lymphadenectomy as part of their staging procedures, and
none were found to have lymph node disease. In contrast, 10% of patients with apparent stage I
SAC of the ovary have been reported to have occult nodal metastasis at the time of diagnosis.
Using the Swedish Family Canter Database of over 6,000 women with a diagnosis of ovarian
cancer showed that the average overall survival was 34 months in women with serous sub‐
types, compared to 70 months for women with mucinous subtypes [72]. In addition, the hazard
ratio for cause-specific survival from MAC compared to SAC was 0.49 (95% confidence inter‐
val, 0.41-0.57); the corresponding hazard ratio for overall survival was 0.56 (95% confidence
interval, 0.48-0.64).
Patients with advanced-stage MAC had a worse prognosis than women with nonmucinous
EOC [73]. The authors matched 27 patients with MAC to 54 patients with nonmucinous ovarian
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cancer (2:1), all of whom had stage III or IV disease and had undergone primary therapy. There
was no difference between patients with the mucinous tumors and nonmucinous with regard
to histological grade, stage, optimal or suboptimal debulking, chemotherapy regimen, or
length of follow-up. Patients with advanced MAC had a progression-free survival of 5.7
months, compared to 14.1 for patients with nonmucinous ovarian cancer, and an overall
survival of 12.0 compared to 36.7 months.
8. Pathological diagnosis for MAC
Most MAC involving the ovary prove to be metastases, as opposed to ovarian primary
carcinomas. Therefore, surgeons and pathologists must have a high suspicion toward meta‐
static disease when considering the origin of MAC found in the ovary. Seidman, et al.[74] found
that only 23% of invasive mucinous carcinomas of the ovary were primary ovarian cancer.
Most clinicians assume that metastases to the ovary have a gastrointestinal origin. However,
although gastrointestinal tract tumors are the most common source of ovarian metastases,
accounting for 45% of such tumors, they also see ovarian metastases from primary tumors of
the pancreas (accounting for 20% of ovarian metastases), cervix (13%), breast (8%), and uterus
(5%). The remaining 10% of ovarian metastases are from unknown primary tumors [68].
At surgical exploration a working differential diagnosis can be developed on the basis of tumor
size and laterality. Among unilateral tumors, more than 80% of those larger than 10 cm are
ovarian primary tumors, while 88% of those smaller than 10 cm are metastases. This division
has been retrospectively validated by other investigators, who showed it to be correct 84% of
the time in differentiating primary from metastatic mucinous carcinomas of the ovary [74].
Other authors also have found this algorithm is useful in predicting the site of origin for ovarian
carcinomas [75, 76]. In addition, primary ovarian carcinomas tend to have a smooth capsule,
while ovarian metastases often involve the gross ovarian surface. However, the algorithm
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Figure 4. Overall survival and residual tumor in mucinous adenocarcinoma (MAC). There was no significant difference
in survival between mucinous invasive adenocarcinoma and serous adenocarcinoma (SAC) in patients with optimal
surgical management. In contrast, patients with suboptimal surgery showed a significantly worse prognosis than
those with serous adenocarcinoma.
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presented above and the status of the ovarian surface should be used clinically with caution:
in one study, up to 24 % of the cases of colonic adenocarcinoma metastatic to the ovary showed
unilateral ovarian involvement with tumor measurements of at least 10 cm [77]. In the same
study, 46% of the cases with available information on gross intraoperative appearance had a
smooth capsule.
Although gross examination of the adnexae can often predict the site of origin, both ovarian
and extraovarian sources of primary disease should be explored. Intraoperatively, the surgeon
should perform a careful exploration of potential gatrointestinal sources, including palpating
the pancreas and running the entire small and large bowel. Postoperatively, the surgeon
should consider a colonoscopy and mammogram if these screening tests have not been
performed within the year prior to diagnosis.
Although the presence of certain histological features can favor a diagnosis of primary MAC
over metastasis, there are cases where a definitive diagnosis cannot be provided due to the
presence of discordant or overlapping features. Microscopic features that favor the diagnosis
of primary ovarian MAC include a coexisting borderline and benign mucinous components,
an expansile pattern of invasion, and a coexisting ovarian teratoma, Brenner tumor, or mural
nodule. In contrast, the following microscopic features favor the diagnosis of metastatic
adenocarcinoma to the ovary: (1) prominent desmoplastic response, (2) nodular pattern of
invasion (i.e., tumor nodules among structures indigenous to the ovarian parenchyma), (3)
small clusters of tumor cell within the corpora lutea or albicantia, (4) numerous pools of mucin
dissecting the ovarian stroma (i.e., pseudomyxoma ovarii) in the absence of a coexistent
ovarian teratoma, (5) an extensive signet ring cell pattern, (6) ovarian surface involvement, (7)
vascular invasion, (8) hilar involvement, and (9) an extensive infiltrative pattern of invasion.
Immunohistochemistry may help determine the primary site of a mucinous carcinoma.
Primary ovarian mucinous carcinomas tend to be positive for CK7 and CK20 with a predom‐
inance of CK7 expression, while colorectal primaries tend to express CK20 only. In addition,
colorectal cancers usually express racemase and beta-catenin while primary mucinous ovarian
cancers do not. In regard to other gynecological primaries metastatic to the ovary, it is worth
mentioning that Human Papilloma Virus (HPV) in situ hybridization can confirm an endo‐
cervical origin because most of the endocervical adenocarcinoma are related to HPV. p16
immunostagining is useful only in well differentiated adenocarcinoma cases where a diffuse
staining will be in keeping with an endocercvical origin.
Attention must be paid to the fact that high-grade ovarian mucinous or endometrioid adeno‐
carcinomas can be positive for p16. Estrogen and progesterone receptors usually are expressed
in endometrioid carcinomas, metastasizing from the endometrium or primary to the ovary.
Metastatic endocervical adenocarcinomas in ovaries cannot be distinguished from a primary
mucinous carcinoma of the ovary because both tumors are progesterone receptor negative and
usually negative for estrogen receptors, although they can have variable expression for the
latter (weak/diffuse or strong/focal staining) [78]. The presence of mesothelin, fascin, and
prostate stem cell antigen (PSCA) favor a pancreatic primary, while the presence of expressed
Dpc4 favors an ovarian primary for differentiating primary ovarian tumors from metastasis
from the pancreas [79]. Most breast cancers are CK7-positive/CK20-negative, unlike ovarian
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primaries which typically express both. In addition, breast cancers almost always express
estrogen receptors as well as gross cystic disease fluid protein (GCDFP)- 15 [80]. Mucinous
ovarian carcinomas are unlikely to express these markers.
Carcinoembryonic antigen (CEA) is a well known serum tumor marker for gastrointestinal
carcinomas. CEA has been noted to be elevated in almost one third of all ovarian carcinomas.
However, CEA is much more likely to be elevated in mucinous ovarian carcinomas than in
nonmucinous ovarian carcinomas (88% vs 19%) [81, 82]. Nolen, et al. [83] compared the levels
of 58 serum biomarkers in serous ovarian carcinomas to mucinous, clear cell, and endoterioid
ovarian carcinomas. Using immunoassays, they found significant differences between the 2
groups for 10 of the biomarkers examined. SAC had significantly higher levels of CA125,
follicle-stimulating hormone, luteinizing hormone, and SMRP. Mucinous tumors had higher
levels of CA72-4, matrixmetalloproteinase-9, CD40L, insulin-like growth factor-binding
protein-1, myeloperoxidase, and tissue plasminogen activator-1.
9. Future directions
Realizing that MAC is a disease distinct from SAC, several collaborative groups have proposed
innovative prospective chemotherapy protocols for patients with advanced or recurrent MAC.
Sato, et al. [84] evaluated 6 different cytotoxic agents in 5 different primary mucinous ovarian
cancer cell lines. All 5 cell lines resisted platinum agents and taxanes given as single agents.
However, 2 of the 5 cell lines were sensitive to oxaliplatin, VP-16, and 5-fluorouracil (5-FU) as
single agents. The investigators then treated the cell lines with oxaliplatin plus VP-16 and
oxaliplatin plus 5-FU. They found that oxaliplatin with 5-FU had was significant inhibition in
4 of the 5 cell lines, whereas the combination of oxaliplatin plus VP-16 was active in only 1 of
the 5 cell lines. Moreover, the combination of oxaliplatin plus 5-FU appeared to be synergistic
by providing significantly more inhibition than either drug alone. The authors then applied
the cell line results to a mouse model of mucinous ovarian cancer xenograft and found that
mice treated with oxaliplatin plus 5-FU survived significantly longer than mice treated with
either agent alone or control mice treated with placebo (Fig 5).
These basic studies led to a single-arm phase II trial of S-1 and oxaliplatin that currently is
enrolling women with advanced or recurrent mucinous ovarian cancer in. S-1 is an orally active
drug made by Taiho Pharmaceuticals that combines 3 separate molecules. The first is tegafur,
a prodrug that is converted to fluorouracil in cells. Next is gimeracil, an inhibitor of dihydro‐
purimidine dehydrogenase, an enzyme that degrades fluorouracil. The third component is
oteracil, a molecule that inhibits the phosphorylation of fluorouracil in the gastrointestinal
tract, reducing gastrointestinal toxicities. The primary endpoint of the study is response rate;
secondary endpoints are toxicity, progression-free survival, and overall survival.
The GOG and the Gynecologic Cancer Intergroup (GCIG) are about to begin accrual to a 4-
arm, phase III, randomized study comparing carboplatin and PTX with and without bevaci‐
zumab to oxaliplatin and capecitabine with and without bevacizumab in women with stage
II-IV or recurrent, untreated, stage I, primary, mucinous ovarian or fallopian tube cancer. The
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primary endpoint will be overall survival; secondary endpoints will be progression-free
survival, response rate, toxicity, and quality of life. The study also assesses the translational
endpoint, KRAS mutations and expression of vascular endothelial growth factor and epider‐
mal growth factor. The targeted accrual for the study is 322 patients.
Based on the similarity of biological characteristics, the standard chemotherapy regimen for
colorectal cancer has been given in patients with MAC. Therefore, the first phase-II chemo‐
therapy study of oral S-1, a 5FU derivative, combined with oxaliplatin (SOX) for advanced or
recurrent patients with MAC was conducted in the Japan ovarian mucinous adenocarcinoma
study group.
We hope that future research in this field will enable to develop an effective strategy for
conquest of chemoresistance in EOC.
Clear cell Serous
No 101 235
Median age 51 (31-72) 54 (23-82)
FIGO stage
Ia 49 (48.5%) 39 (16.6%)
Ib 11 (10.9%) 15 ( 6.5%)
Ic 0 2 ( 0.9%)
II 38 (37.6%) 22 (9.4%)
III 10 (9.9%) 145 (61.7%) P<0.0001
IV 31 (30.7%) 38 (16.2%)
Table 1. Patients Characteristics
Figure 5. Survival in mice with mucinous adenocarcinoma cells (TU-OM-1 cell). Mice treated with oxaliplatin and 5-FU
survived significantly longer than mice treated with either agent alone or control mice.
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